BIXT — BIOXYTRAN, INC
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1445815 ·
Last close
$0.03
Market Cap
$3.17M
52W High
$0.05
52W Low
$0.03
ADV30
48,947
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,935,161 | -2,068,989 | 615,253 | 463,047 | 5,010,121 |
| Dec 2025 | 0 | — | -610,232 | -522,155 | 658,552 | 509,914 | 3,249,894 |
| Sep 2025 | 0 | — | -500,241 | -282,726 | 156,294 | 14,499 | 3,060,937 |
| Jun 2025 | 0 | — | -226,588 | 35,437 | 147,501 | 3,144 | 2,782,771 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-597,742
Investing CF
$-32,303
Financing CF
$1,088,744
CapEx
$-32,303
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.04
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-23,113,235
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-2,623,441
Pretax Income TTM
$-2,838,433
Interest Exp TTM
$214,992
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,854,053 | -2,123,077 | 658,552 | 3,249,894 | — | -526,455 |
| Dec 2024 | 0 | -2,231,018 | -2,366,681 | 138,694 | 1,930,642 | — | -381,316 |
| Dec 2023 | 0 | -3,808,497 | -4,472,525 | 139,382 | 3,244,238 | — | -775,375 |
| Dec 2022 | 0 | -2,440,185 | -2,473,134 | 370,936 | 3,667,911 | — | -1,803,670 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DCOY | Decoy Therapeutics Inc. | $3.20M | $6.01 | — |
| CDT | CDT Equity Inc. | $3.38M | $0.70 | — |
| CMND | Clearmind Medicine Inc. | $3.40M | $3.34 | — |
| AZTR | Azitra, Inc. | $3.43M | $0.21 | — |
| LSBCF | LakeShore Biopharma Co., Ltd. | $2.88M | $0.07 | — |
News headlines (Yahoo Finance, 1h cache)
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
2026-05-29 12:03 · Yahoo
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
2026-03-20 13:05 · Yahoo
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
2026-03-04 20:40 · Yahoo
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
2026-03-02 16:40 · Yahoo
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus
2026-02-23 12:00 · Yahoo
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
2026-02-17 13:00 · Yahoo
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
2026-02-11 11:00 · Yahoo
Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference
2026-02-04 21:25 · Yahoo
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
2026-02-02 12:00 · Yahoo
Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline
2026-01-29 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.